STAT+: Sales from controversial drug discount program rose to $54 billion last year
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $53.7 billion in 2022, an 18% increase from the previous year.
Prescription medicines purchased in the U.S. under a controversial government discount program amounted to $53.7 billion in 2022, an 18% increase from the previous year, according to the U.S. Health Resources & Service Administration, which oversees the program.
The latest data mark a steady rise in sales under the 340B Drug Discount Program, which requires drugmakers to offer discounts that are typically estimated to be 25% to 50% — but could be higher — of all outpatient drugs used by hospitals and clinics that primarily serve lower-income patients. There are roughly 12,400 entities participating in the program, a number that has grown substantially.
Since it began 30 years ago, the program has ballooned and fed into the national clash over the cost of medicines. Some $44 billion in medicines were purchased under the 340B program in 2021, which was up from $38 billion the previous year. In 2016, 340B sales were $16.2 billion.
What's Your Reaction?
